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Abstract
Aims: Subgroups of patients with type 2 diabetes mellitus demand large insulin doses to maintain euglycemia. These
patients are characterized by severe skeletal muscle insulin resistance and the underlying pathology remains unclear. The
purpose of this study was to examine protein expression of the principal glucose transporter, GLUT4, and associated
proteins in skeletal muscle from type 2 diabetic patients characterized by severe insulin resistance.
Methods: Seven type 2 diabetic patients with severe insulin resistance (mean insulin dose 195 IU/day) were compared with
seven age matched type 2 diabetic patients who did not require insulin treatment, and with an age matched healthy
control group. Protein expression of GLUT4 and associated proteins was assessed in muscle and fat biopsies using standard
western blotting techniques.
Results: GLUT4 protein expression was significantly reduced by ,30 pct in skeletal muscle tissue from severely insulin
resistant type 2 diabetic subjects, compared with both healthy controls and type 2 diabetic subjects that did not require
insulin treatment. In fat tissue, GLUT4 protein expression was reduced in both diabetic groups. In skeletal muscle, the
reduced GLUT4 expression in severe insulin resistance was associated with decreased ubiquitin-conjugating enzyme 9
(UBC9) expression while expression of GLUT1, TBC1D1 and AS160 was not significantly different among type 2 diabetic
patients and matched controls.
Conclusions: Type 2 diabetic patients with severe insulin resistance have reduced expression of GLUT4 in skeletal muscle
compared to patients treated with oral antidiabetic drugs alone. GLUT4 protein levels may therefore play a role in the
pathology behind type 2 diabetes mellitus among subgroups of patients, and this may explain the heterogeneous response
to insulin treatment. This new finding contributes to the understanding of the underlying mechanisms for the development
of extreme insulin resistance.
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Introduction
Type 2 diabetic patients with extreme insulin resistance
represent a major therapeutic challenge in terms of achieving
glycaemic goals. Many patients require several hundred units of
insulin daily, but despite large amounts of daily insulin, glycemic
control remains poor, and it may be difficult to decide whether to
increase insulin dosages further or regard patients as being non-
compliant. It is unknown whether such patients have defects in the
mechanisms that control insulin stimulated glucose uptake.
Skeletal muscle is the predominant tissue for insulin stimulated
glucose disposal in humans [1]. Glucose enters the muscle cell
primarily by facilitated diffusion, utilizing glucose transporter
carrier proteins [2]. GLUT4 is the predominantly expressed
glucose transporter isoform in muscle, whereas the GLUT1
isoform is expressed at much lower abundance [2]. In healthy
subjects, whole body glucose disposal and GLUT4 expression
correlate [1]. Glucose uptake through GLUT4 is regulated by
insulin [2]. After binding to its receptor, insulin stimulates an
intracellular signaling cascade that ultimately results in the
phosphorylation of the Rab-GTPase-activating proteins AS160
(TBC1D4) and TBC1D1 [3]. When AS160 and TBC1D1 are
phosphorylated on key residues, GLUT4 is released and
translocates to the cell surface where it docks and fuses with the
membrane [3]. After translocation to the cell surface, GLUT4 can
either be recycled back to intracellular vesicles or be targeted for
lysosomal degradation [4]. This process is regulated by ubiquitin-
conjugating enzyme 9 (UBC9) which controls attachment of Small
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degradation of GLUT4 in L6 muscle cells [5]. Similar observa-
tions have been made in 3T3-L1 adipocytes where overexpression
of UBC9 promotes accumulation of GLUT4, whereas RNAi-
mediated depletion of UBC9 causes a selective loss of GLUT4 [6].
Resistance to insulin in skeletal muscle and impaired insulin
stimulated glucose uptake is a prominent feature of type 2 diabetes
mellitus. This is associated with reduced insulin stimulated
GLUT4 translocation demonstrated by labeling of GLUT4 on
the cell surface [7], most likely caused by a reduced insulin
signaling from the insulin receptor [8]. In adipose tissue, type 2
diabetes is associated with reduced GLUT4 expression [2], but in
patients that maintain euglycemia on diet and treatment with oral
antidiabetic drugs, the impaired translocation is not due to
reduced expression of GLUT4 in skeletal muscle [2,9–11].
However, type 2 diabetic patients who daily require high doses
of insulin may have additional pathological defects in their
muscles, and understanding these mechanisms is important for
optimizing treatment. We therefore examined expression of
GLUT4 and associated proteins in skeletal muscle from type 2
diabetic patients characterized by severe insulin resistance.
Methods
The studies were conducted in accordance with the Helsinki
Declaration and the study protocols were approved by the Ethical
Committee of Central Denmark Region. Informed consent was
obtained in writing from all subjects before participation.
Three groups were included: 1) type 2 diabetic patients with
severe insulin resistance (T2DSI), defined as insulin requirements
of more than 100 units/day, this group has been described
previously [12], 2) a group of age matched type 2 diabetic patients
treated with oral anti-diabetics or diet alone (T2DOAD), and 3) an
age matched control group without concomitant disease. All
participants had normal renal and hepatic function assessed by a
blood test before they were included in the study. Oral anti-
diabetic treatment was withdrawn two days before the study in
both diabetic groups. The day before the study the patients in the
T2DSI group had their usual insulin treatment replaced with short
acting insulin (Actrapid; Novo Nordisk, Bagsværd, Denmark). All
other treatments continued during the study. Average duration
and type of daily physical activity was registered by the
participants, and the data are presented as active hours per week.
None of the participants were engaged in any type of strenuous
physical activity. After an 8-h overnight fast, the subjects had
Table 1. Clinical and metabolic characteristics.
Controls T2DOAD T2DSI P-value
Men/Women 6/1 3/4 5/2
Insulin requirements (IU/day) 195626
Age (Years) 59.462.0 64.063.2 58.962.6 0.34
BMI (kg/m
2)2 8 . 0 61.5 31.862.4 35.762.1 0.050
Fasting plasma glucose (mmol/l) 5.360.2
a 7.860.3
b 7.960.4 ,0.001
HbA1c (%) 6.860.2 8.860.6 0.006
e
Insulin (pmol/l) 6868
a 126632
a 350646 ,0.001
C-peptide (pmol/l) 8096100 15686241
ac 6416148 0.003
Total cholesterol (mmol/l) 5.760.3
a 4.360.2
b 4.060.3 ,0.001
LDL cholesterol (mmol/l) 3.5 (3.3; 3.6) 2.0 (1.8; 2.0)
d 2.2 (1.7; 2.4)
d 0.002
HDL cholesterol (mmol/l) 1.6 (1.2; 1.9) 1.4 (1.0; 1.8) 1.0 (0.8; 1.2) (n=6)
c 0.04
Triglycerides (mmol/l) 1.4 (1.2; 1.6) 1.5 (0.9; 3.3) 2.6 (1.4; 3.0) 0.63
Systolic BP (mmHg) 129651 3 6 64 14065 0.21
Diastolic BP (mmHg) 85627 5 638 2 64 0.09
Serum creatinine (mmol/l) 77657 1 658 5 67 0.25
Activity (hours/week) 2.3 (0.0; 4.0) 3.0 (1.9; 6.3) 0.0 (0.0; 1.8) 0.06
Diabetes duration (Years) 3.961.5 17.364.1 0.01
All data are presented as means6SE or median (range), (n =7 unless indicated otherwise). T2DSI = type 2 diabetes, severely insulin resistant, T2DOAD = type 2
diabetes, oral antidiabetics, diet.
M-value, Insulin and C-peptide are mean values obtained during the last 30 minutes of the hyperinsulinemic euglycemic clamp.
P-value is result of ANOVA testing. Post-hoc test were performed when indicated:
a.P,0.001 vs. T2DSI,
bP,0.001 vs. controls,
cP#0.01 vs. controls,
dP,0.05 vs. controls.
doi:10.1371/journal.pone.0027854.t001
Table 2. Comparison of clamp data (last 30 minutes of the
hyperinsulinemic euglycemic clamp).
T2DOAD T2DSI P-value
M-value (mg/kg/
min)
2.9(2.4; 5.5) 1.3(1.0; 2.9) 0.037
Insulin (pmol/l) 796693 1112662 0.016
C-peptide (pmol/l) 11266218 364696 0.017
All data are presented as means6SE or median (range) (n=7). T2DSI = type 2
diabetes, severely insulin resistant, T2DOAD = type 2 diabetes, oral
antidiabetics, diet.
doi:10.1371/journal.pone.0027854.t002
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was obtained under local anesthesia using a Bergstro ¨m needle.
The muscle biopsies were snap-frozen in liquid nitrogen and
stored at 280uC until analyses were performed. One hour after
the biopsy was taken the diabetic subjects underwent a 150 min
hyperinsulinemic euglycemic clamp. In short, insulin (Actrapid)
was infused at a rate of 5 ml/hour (1.5 mU*kg
21*min
21), and
plasma glucose was clamped at 6 mM by infusion of a 20%
glucose solution. Insulin sensitivity was estimated by the rate of
glucose infusion required to maintain euglycemia during the
insulin infusion and expressed as insulin stimulated glucose uptake
(M-value). Body composition (Total Body Water (TBW)) was
estimated by using single frequency bioelectrical impedance
analysis (SF-BIA; BIA 101, RJL-Systems, MI, USA). TBW was
calculated by using the equation TBW =r6length
2/Z [13].
Blood samples and measurements
Plasma glucose was measured on a Beckman Glucoanalyzers
(Beckman Instruments, USA). Plasma creatinine, lipids, and
HbA1c were determined by standard laboratory techniques.
Insulin was analysed using TR-IFMA (AutoDELFIA, PerkinEl-
mer, Finland) and C-peptide was measured by ELISA (DakoCy-
tomation, United Kingdom).
Western Blot analysis
Protein expression was assessed using standard western blotting
techniques [14,15]. In short, biopsies (,30 mg) were homogenized
in a buffer containing: 50 mM HEPES, 137 mM NaCl, 10 mM
Na4P2O7, 10 mM NaF, 1 mM MgCl2, 1 mM CaCl2,2 m M
EDTA, 1% NP240, 10% glycerol, 2 mM Na3VO4, 100 mM
AEBSF [4-(2-aminoethyl) benzenesulfonyl fluoride, hydrocloride],
pH 7.4. Protein expression was assessed using standard western
blotting techniques. In short, protein was separated on a 4–12%
Bis-Tris SDS gel (Criterion
TM XT, Bio-Rad, CA, USA),
transferred to a PVDF membrane, and immunoblotted. b-actin
(Abcam, #ab82227-50) was used as a control for equal loading.
Antibodies against GLUT4 were generated as previously de-
scribed [16] and commercially available antibodies against: AS160
(Cell Signalling, #2447), TBC1D1 (Abcam, #ab56191-100),
UBC9 (Abcam, #ab75854), and GLUT1 (Millipore, #07-1401)
were used. HRP-conjugated goat anti-rabbit IgG (#NA934, GE
healthcare) was used as secondary antibody.
Figure 1. Total protein content in muscle biopsies. Protein content was assessed by western blotting analysis of GLUT4 (A), UBC9 (B), GLUT1
(C), TBC1D1 (D), and AS160 (E). All protein expressions are corrected for b-actin levels. Data are presented as mean + SE. *: P,0.05 versus control and
T2DOAD.
doi:10.1371/journal.pone.0027854.g001
Figure 2. GLUT4 protein content in fat biopsies. Protein content was assessed by western blotting analysis of GLUT4 and corrected for b-actin
levels. Data are presented as mean + SE. *: P,0.05 versus control and T2DOAD.
doi:10.1371/journal.pone.0027854.g002
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Skeletal muscle (20 mg) was homogenized in TriZol reagent
(Gibco BRL, Life Technologies, Roskilde, Denmark). RNA was
quantified by measuring absorbence at 260 nm and 280 nm and
the integrity of the RNA was checked by visual inspection of the
two ribosomal RNAs on an ethidium bromide stained agarose gel.
Real-time RT-PCR for mRNA analysis
Reverse transcription was performed using random hexamer
primers as described by the manufacturer (GeneAmp RNA PCR
Kit from Perkin Elmer Cetus, Norwalk, CT). PCR-mastermix
containing the specific primers and Taq DNA polymerase
(HotStar Taq, Quiagen Inc. USA) was added. The following
primers were designed using the primer analysis software Oligo
version 6.64:
SOCS3:, CGG CCA CCT GGA CTC CTA TGA and GCC
CTT TGC GCC CTT T
PTP1:; GCA CCC TAC GGC ATC GAA AG and GCA GCC
TGG GCA CCT CGA AGA
GLUT4: GCA CCG CCA GGA CAT TGT TG and CCC
CCT CAG CAG CGA GTG A
b2-microglobulin: AAT GTC GGA TGG ATG AAA CC and
TCT CTC TTT CTG GCC TGG AG
Real time quantitation of target gene to b2-microglobulin
mRNA was performed with a SYBR-Green real-time PCR assay
using an ICycler from BioRad. The threshold cycle (Ct) was
calculated, and the relative gene-expression was calculated
essentially as described in the User Bulletin #2, 1997 from Perkin
Elmer (Perkin Elmer Cetus, Norwalk, CT).
Statistics
Results are expressed as mean6SE (parametric data) or median
and range (non-parametric data). Statistical comparisons among
groups were performed by One-Way ANOVA using SigmaPlot
11.0 (Systat Software inc. San Jose, CA, USA). LDL, HDL, TG,
M-values, UBC9 expression, Real-time RT-PCR and activity
levels were logarithmically transformed before applying paramet-
ric tests. Post hoc comparisons were performed with Holm-Sidak’s
test (parametric data) or Dunn’s test (non-parametric data).
Comparisons between two groups were assessed using a two-
sample t-test. All data presented in tables have been re-
transformed in order to make values immediately recognizable.
P,0.05 was considered statistically significant.
Results
Clinical characteristics of the participants are summarized in
Table 1. On average, the T2DSI group received an insulin dose of
195 IU/day. Insulin treatment comprised either Novomix (n=5),
Lantus (n=1), or Insulatard and Actrapid in combination (n=1).
Six of the T2DSI subjects received oral anti-diabetic treatment
(Metformin only). The T2DOAD group (n=7) was treated with
either diet alone (n=2), or diet combined with metformin (n=3),
or sulfonylurea and rosiglitazone (n=2). Additional medication
among the three groups comprised the following: in the T2DSI
Figure 3. Gene expression of GLUT4, SOCS3 and PTP1B. mRNA
levels in skeletal muscle was measured by quantitative PCR using beta2-
microglobulin as housekeeping gene. GLUT4 mRNA was reduced in
skeletal muscle from both diabetic groups. GLUT4 gene expression is
presented as mean + SE. SOCS3 and PTP1B expressions were not
normally distributed and data are presented as median + 75%
percentile *: P,0.05 versus control and T2DOAD.
doi:10.1371/journal.pone.0027854.g003
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licylic acid (n=7), levothyroxine (n=1), antidepressants (n=2),
antacida (n=1), NSAID besides acetylsalicylic acid (n=1); in the
T2DOAD group: statins (n=5), antihypertensive treatment
(n=7), acetylsalicylic acid (n=2), levothyroxine (n=2), allopurinol
(n=2), NSAID besides acetylsalicylic acid (n=1) and in the
Control group: NSAID besides acetylsalicylic acid (n=1) and
fenytoin (n=1).
BMI did not differ significantly among the groups, although
there was a tendency for increased BMI in the TD2SI group
(P=0.05). Body composition, expressed by TBW, was 25.361.3,
26.261.7 and 29.660.9 in controls, T2DOAD, and T2SI
respectively and were not statistically significantly different
(P=0.15). Diabetes duration was ,4 fold longer and HbA1c was
significantly higher among T2DSI compared to T2DOAD. The
M-value, a measurement of insulin sensitivity, was ,50% lower in
the T2DSI group compared to the T2DOAD group (Table 2). All
groups were characterized by a low physical activity level
(,3 hours weekly) and none of the participants participated in
any kind of vigorous exercise. Total and LDL cholesterol were
significantly higher among controls compared to the diabetic
groups.
As depicted in Figure 1A GLUT4 expression, normalized for b-
actin, was reduced by ,30% in skeletal muscle from the T2DSI
group with no difference between controls and type 2 diabetic
patients in the T2DOAD group. This was associated with a
decreased expression of UBC9 (Fig 1B). GLUT1 expression was
also reduced in skeletal muscle in the T2DSI group, but this
difference did not reach statistical significance (P=0.21). Expres-
sion of TBC1D1 and AS160 in skeletal muscle was similar among
type 2 diabetic patients and matched controls. As shown in
figure 2, GLUT4 expression in adipose tissue was reduced in both
groups of diabetic patients with the most predominant reduction in
patients with severe insulin resistance. GLUT4 gene expression in
skeletal muscle was decreased in both diabetic groups as shown on
figure 3A. We could only detect low gene expression levels of
SOCS3 and PTP1B (Fig 3B and 3C), both negative regulators of
insulin signaling [17,18], and the differences in expression levels
were not statistically significant.
Discussion
The data from the current study demonstrate that reduced
GLUT4 expression in skeletal muscle is a pathological component
in a subgroup of type 2 diabetic patients with severe insulin
resistance. This finding challenges the current dogma, that
GLUT4 expression is normal in muscle from type 2 diabetic
patients [2,9–11]. This perception is mainly based on data from
patients that do not require insulin, and in agreement with these
findings we did not see reduced GLUT4 expression in a matched
group of patients not treated with insulin. Our observation was
done in a small group of subject and larger studies are needed to
determine to which degree reduced GLUT4 expression is a part of
the pathogenesis behind insulin resistance in other groups of type 2
diabetic patients.
GLUT4 protein levels are positively associated with insulin
sensitivity in humans [1,19], but GLUT4 expression does not
necessarily reflect translocation to the cell surface during insulin
stimulation. SOCS3 and PTP1B levels were not significantly
increased in the diabetic subjects, but it is well-established that
patients with type 2 diabetes mellitus have defects in the insulin
signaling cascade that stimulate GLUT4 translocation [2].
Therefore the combination of impaired insulin signaling and
reduced GLUT4 expression is likely to further aggravate the
therapeutic challenge of normalizing glucose levels among this
group of diabetic patients.
Gene expression of GLUT4 was reduced in both groups of
diabetic patients, but only patients with severe insulin resistance
had decreased UBC9 expression. This indicates that the reduced
GLUT4 protein level is due to a combined effect of reduced
production and increased GLUT4 degradation. In healthy
humans, prolonged insulin stimulation during a hyperinsulinemic
euglycemic clamp is associated with a reduction of GLUT4
protein levels in skeletal muscle [20]. It is possible that prolonged
stimulation with exogenous insulin disrupts GLUT4 recycling, and
this leads to increased GLUT4 degradation. In patients with
severe insulin resistance this could cause a vicious cycle where the
progressive increase in insulin dosage cause a reduction in GLUT4
levels and thereby increase the need for further insulin treatment.
Reduced GLUT4 levels in adipose tissue from patients with
type 2 diabetes have previously been observed [2]. This defect is
also present in adipose tissue from subject in high risk of
developing diabetes [21,22] and is associated with alterations in
the endocrine function of adipocytes [23]. Our finding show that
GLUT4 expression in further decreased in patients with severe
insulin resistance compared to diabetic patients with a less severe
insulin resistance.
Skeletal muscle also expresses the glucose transporter GLUT1,
although at lower levels than GLUT4 [2]. GLUT1 is mainly
responsible for basal glucose uptake, but an increase in GLUT1
expression could potentially compensate for a reduced GLUT4
level. However, similar to previous observations [11] we saw a
tendency to lower GLUT1 expression in patients with severe
insulin resistance, although this difference did not reach statistical
significance. TBC1D1 and AS160 are negative regulators of
insulin stimulated glucose uptake [3], but the severe insulin
resistance was not associated with alterations of TBC1D1 and
AS160 on a protein expression level.
In conclusion, we found that GLUT4 expression is reduced in
skeletal muscle from type 2 diabetic patients who despite being
treated with more than 100 units of insulin daily have poor
glycemic control. This challenges the dogma that altered GLUT4
protein levels do not contribute to insulin resistance in humans.
Instead, reduced GLUT4 expression may partly explain the severe
insulin resistance and poor glycemic control among type 2 diabetic
patients with severe insulin resistance.
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